Pages tagged "Research"
Earlier this month, there were two exciting developments for medical cannabis internationally. In Israel, a Tel Aviv medical clinic began dispensing medical cannabis to patients in need, while in Canada, a federal court ruling ended the monopoly a federal contractor has on supplying cannabis to patients, opening up possibilities for dispensaries and collective production of medicine. Our international counterparts may be surging ahead in their paths to provide safe access for patients who benefit from medical cannabis, but here in the US, it's sometimes hard to move to the conversation about access when our government barely budges on research issues. The DEA continues to uphold a monopoly on the production of cannabis for research, even though it's own administrative law judge recommended ending this monopoly by granting a license to Professor Lyle Craker to grow research material. While whole plant medical cannabis is being stonewalled though, GW Pharmaceuticals is moving rapidly through Phase III trials in the US for Sativex, a cannabis-based tincture. GW's chairman, Dr. Geoffrey Guy, had this to say about the progress of Sativex:
"2008 promises to be an equally eventful year for GW, with the results of a number of key Sativex Phase III trials in Europe and the US due to be reported. The momentum behind Sativex and the wider field of cannabinoid medicines, as highlighted today by the promising results of our THCV metabolic research programme, continues to grow..."It's good to know that GW recognizes the potential for a wider field of cannabis medicine, but until the monopoly on production of cannabis for research is ended, it will be difficult for researchers to push this field forward in the United States. Until then, at least patients in Israel are happy: "One cancer patient said the ministry's decision to offer the drug through the clinic was "a blessing," saying it prevents suffering patients from being driven to buy the drug illegally."
On Saturday, December 1, to commemorate Worlds AIDS Day, Democratic Presidential Candidate, New Mexico Governor Bill Richardson unveiled his HIV/AIDS policy platform. In addition to recognizing the need for a National AIDS Strategy, the Governor’s plan includes a provision that would permit the use of medicinal marijuana to help people living with HIV/AIDS improve pain and symptom management. The anti-emetic and analgesic properties of cannabis have been particularly useful to HIV/AIDS patients. People living with HIV/AIDS have long used cannabis to help with symptoms of HIV related illnesses ranging from wasting and loss of appetite to adherence to medications. Consequently, it is estimated that as many as 1 in 4 AIDS patients use cannabis for medical purposes. Earlier this year, the journal Neurology published the results of a clinical trial indicating that smoked marijuana can alleviate painful, peripheral HIV/AIDS-related neuropathy. Research also shows that access to cannabis may improve health care outcomes for people living with HIV/AIDS. For example individuals who use cannabis in conjunction with their antiretroviral therapy are approximately 3.3 times more likely to remain on their prescribed drug therapies than those who do not use cannabis. The Bush Administration has failed to acknowledge the growing body of evidence which demonstrate that marijuana has medical value. In fact, neither the Clinton nor the Bush Administrations have ever undertaken any effort to review or fully implement the recommendations of the 1999 Institute of Medicine (IOM) study, Marijuana and Medicine-Assessing the Science, which acknowledged that "For patients such as those with AIDS or who are undergoing chemotherapy and who suffer simultaneously from severe pain, nausea, and appetite loss, cannabinoid drugs might offer broad-spectrum relief not found in any other single medication." In contrast, California and 12 other states, including New Mexico, have passed laws that authorize the use of cannabis by qualified patients who possess a recommendation from their physicians. Americans for Safe Access is encouraged by Governor Richardson’s sensitivity to the intersection of medical marijuana and HIV/AIDS. We hope other Presidential candidates will take note, and follow his lead.
From our friends at MAPS:
In late September, DEA proposed a new rule that would effectively place dronabinol (the active chemical in MARINOL) in Schedule III. Wait a second, isn't MARINOL already in Schedule III? It is. When MARINOL was first marketed, it was placed in Schedule II. Once DEA was shown that it had a low potential for abuse, they agreed to place it in Schedule III. But the narrow language only places in Schedule III MARINOL's specific formulation (synthetically derived dronabinol, suspended in sesame oil). All other formulations remain in Schedule I.Marinol's patent is almost up, which will open up the market to generic dronabinol, as long as the rule change goes through. ASA submitted a Public Comment in support of the proposed rule change. Here are some highlights:
Primarily, the proposed rule is a positive step because in it, the DEA acknowledges, only for the second time (Marinol was the first in 1986), the obvious medical benefits of THC/dronabinol. These proposed changes also represent progress because they implicitly recognize the value of whole-plant cannabis and its capacity to extract naturally occurring THC that is bioequivalent to synthetic THC... This proposed change is also a positive development because its will likely result in greater access for patients to less expensive, naturally derived cannabis-based drugs in the short term... Generic drugs, drugs that are produced and distributed without patent protection (and approved by the FDA under 21 U.S.C. 355 § 505(j)), are generally much cheaper than brand-name drugs, such as Marinol.We go on to argue that the rule change does not go far enough, and that the DEA needs to consider rescheduling other cannabinoids:
...the DEA should initiate another proposed rule change that reschedules a wide array of natural, non-psychoactive phytocannabinoids to support the research and development of a wider variety of cannabis-based medicines. Research suggests that the beneficial therapeutic effects of cannabis may result from the interaction, or synergy, among various cannabinoids. This helps to explain why medicines developed from whole-plant extracts may be more effective than single cannabinoid drugs developed from synthetic compounds. For instance, Sativex is a cannabis-based medicine, which combines both THC and CBD to produce an entirely different therapeutic potential than THC alone, has been developed by UK-based GW Pharmaceuticals, and has been approved for use in Canada and is undergoing clinical trials in Europe and the United States...And we further argue that the DEA should end the obstructions to medical cannabis research:
...the DEA should accept the opinion of its own U.S. Department of Justice-appointed Administrative Law Judge (ALJ) Mary Ellen Bittner, who urges the DEA to grant a license to Professor Lyle Craker to cultivate research-grade cannabis for distribution exclusively to federally approved researchers, which would greatly facilitate research on the therapeutic value of cannabis and access to its naturally derived constituent cannabinoids, specifically THC.Please read ASA's full comment and MAPS' comment.
ASA Participates in the National Multiple Sclerosis Society's National Conference! This week, ASA Executive Director, Steph Sherer, Government Affairs Director, Caren Woodson, and I traveled to Dallas, Texas to attend the annual National Multiple Sclerosis Society's 2007 National Conference in an effort to continue to build a coalition of condition-based groups and expand ASA MS Patients' Union. We staffed our educational outreach exhibit and discussed safe access to marijuana with a receptive audience of people living with MS, their family-members, caregivers, and advocates. We also were afforded the opportunity to broaden our knowledge about both the National MS Society and the innovations in Multiple Sclerosis research and treatment. The overall reception from conference participants has been very encouraging. Many people remembered us from last year's conference. Others were introduced to medical cannabis as treatment for symptoms associated with MS for the first time. Building on the momentum generated from an article published earlier this year by InsideMS, "Considering Cannabis," We have been introducing several MS Society chapter leaders, members, and staff to the therapeutic benefits of cannabis and it's ability to treat several symptoms associated with MS. Since ASA participated in last year's conference, the National MS Society has implemented a Cannabis Task Force, led by MS expert, Dr. Alan J. Thompson, to, "review published studies on medical marijuana and make recommendations." Read more about the objectives of the task force in the Considering Cannabis article. Click here to read more about ASA's Patients' Unions.